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Abstract
Background: Loxoprofen is a nonsteroidal anti-inflammatory drug used in the treatment of many diseases.
However, there are no case reports about loxoprofen-induced pneumonia. We have encountered a rare case
of loxoprofen-induced pneumonia.
Case presentation: We report the case of a 71-year-old Japanese woman who was initially treated with loxoprofen for
fever.
She was admitted to our hospital because of worsening of her symptoms, including fever and dyspnea. Her symptoms
improved after treatment with ceftriaxone. Seven days after admission, she again developed high fever. She was again
treated with loxoprofen and levofloxacin. However, acute respiratory failure developed after initiation of loxoprofen
treatment. Chest computed tomography showed peribronchovascular consolidation. She was diagnosed with
loxoprofen-induced pneumonia for which she was administered steroids. After treatment, her dyspnea and radiological
findings improved.
Conclusions: The findings in this case report reveal an association between treatment with a nonsteroidal anti-
inflammatory drug and pneumonia. This rare case was diagnosed after accidental retreatment with loxoprofen.
This is the first report of loxoprofen-induced pneumonia.
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Background
Loxoprofen is a nonsteroidal anti-inflammatory drug
(NSAID) that alleviates inflammation and pain by nonse-
lective inhibition of the cyclooxygenase pathway. Many
clinicians worldwide routinely administer loxoprofen to
patients with cold symptoms and acute upper respiratory
inflammation. The major side effects of loxoprofen in-
clude gastric inflammation, ulcers, and renal dysfunction.
However, development of interstitial pneumonia is a very
rare side effect of loxoprofen. Here we report the first case
of interstitial pneumonia induced by loxoprofen.
Case presentation
A 71-year-old Japanese woman presented to our hospital
with high fever and severe cough, and was admitted for
bacterial pneumonia. Before her admission, she had de-
veloped fever and cough, and had received treatment
with the anti-inflammatory drug loxoprofen. However,
her symptoms deteriorated. Her initial vital signs on
admission were as follows: temperature, 37.8 °C; respira-
tory rate, 18 breaths/minute; and oxygen saturation
(SpO2) on room air, 94 %. A physical examination re-
vealed fine crackles in both her lower lung fields. Her
laboratory test values were as follows: white blood cell
(WBC) count, 6000/μL; neutrophil count, 3780/μL;
serum lactate dehydrogenase (LDH) level, 230 IU/L
(normal, 119 to 229 IU/L); and serum C-reactive protein
(CRP) level, 6.3 mg/dL (normal, <0.3 mg/dL). A chest
radiograph (Fig. 1a) showed reticular shadows in both
her lower lung fields. Chest computed tomography (CT;
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Fig. 2a) showed consolidation. A sputum Gram stain re-
vealed only normal bacterial flora. Mycoplasma antigen
was absent. Urinary antigen tests for Legionella and
Streptococcus pneumoniae also yielded negative results.
She was treated with ceftriaxone (2.0 g/day) for 7 days.
She was retreated with loxoprofen a few times when she
had high fever and pain. After these treatments, al-
though her symptoms resolved almost completely, she
still had a slight fever. Chest radiograph findings showed
improvement of reticular shadows in almost all her lung
fields. However, 7 days after initiation of ceftriaxone
treatment, she again developed high fever. She was
treated with loxoprofen to alleviate her fever, and the
antibiotic was changed from ceftriaxone to levofloxacin.
After 3 days, she had intermittent high fever, severe
cough, and dyspnea, which gradually worsened. Her ini-
tial vital signs at this time were as follows: temperature,
39.0 °C; respiratory rate, 24 breaths/minute; and SpO2
on room air, 88 %. A physical examination revealed fine
crackles in both her lower lung fields. Her laboratory
test values were as follows: WBC count, 10,600/μL with
a left shift; neutrophil count, 9110/μL; serum LDH level,
255 IU/L; serum CRP level, 14.8 mg/dL; Krebs von den
Lungen-6 (KL-6) level, 320 IU/L (normal, <500 IU/L);
surfactant protein-D (SP-D) level, 140 ng/mL (normal,
<110 ng/mL); and plasma (1→3) beta-D-glucan level, 13
pg/dL (normal, <20 pg/mL). Arterial blood gas values
obtained on 3 L/minute oxygen delivered via nasal can-
nula were as follows: pH, 7.45; partial pressure of oxygen
in arterial blood (PaO2), 58 Torr; partial pressure of
carbon dioxide in arterial blood (PaCO2), 36 Torr; and
bicarbonate level, 27 mg/dL. A chest radiograph (Fig. 1b)
showed areas of bilateral ground-glass opacity in almost all
her lung fields. A chest CT scan (Fig. 2b) revealed bilateral,
peripheral, subpleural peribronchovascular consolidation in
almost all her lung lobes. Sputum, urine, and blood cultures
yielded negative results. Four days after she was treated
with loxoprofen for recurrent high fever, we performed
bronchoalveolar lavage (BAL) from the left B4. The total
cell count and lymphocytes in her BAL fluid were
elevated to 5.0×105/mL and 38 %, respectively. The
result of a drug lymphocyte stimulation test (DLST)
in peripheral blood was strongly positive (stimulation
index, 330 %) for loxoprofen and negative for ceftri-
axone and levofloxacin. The patient was diagnosed with
loxoprofen-induced pneumonia. Her respiratory status
rapidly worsened after BAL; therefore, she was treated im-
mediately with high-dose methylprednisolone therapy (1
g/day for 3 days) for acute respiratory failure. Her respira-
tory status and chest radiography findings improved
dramatically after initiation of steroid therapy (Fig. 1c).
The patient had a Naranjo adverse drug reaction (ADR)
probability score of 6 (Table 1), so her symptoms were
classified as a probable ADR [1].
Discussion
To the best of our knowledge, this is the first English-
language case report of loxoprofen-induced pneumonia.
There have been a few case reports of NSAID-induced
pneumonia and eosinophilic pneumonia in Japan. These
reports include cases of loxoprofen-induced hypersensi-
tivity pneumonia [2] and loxoprofen-induced
Fig. 1 Chest X-ray images. a Chest X-ray on admission. b Chest X-ray at the time of worsening of respiratory failure. c Chest X-ray after steroid treatment
Fig. 2 Chest computed tomography images. a Chest computed tomography on admission. b Chest computed tomography at the time of worsening of
respiratory failure
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eosinophilic pneumonia [3]. However, there is no report
on the incidence of NSAID-induced pneumonia. In gen-
eral, the incidence of drug-induced lung disease (DILD)
is higher in Japanese than in white patients. For example,
in the case of gefitinib, which is the major epidermal
growth factor receptor tyrosine kinase inhibitor for non-
small cell lung cancer, the incidence of DILD is approxi-
mately 2.0 % in Japan, which is higher than that in the
USA (0.3 %) [4]. Meanwhile, in the field of idiopathic
pulmonary fibrosis (IPF), it has been revealed that some
genetic backgrounds, such as telomere length, telomer-
ase mutation, and MUC5B promoter polymorphism, are
associated with the development of fibrosis in the white
population [5]. However, it has been reported that the
MUC5B promoter polymorphism frequency in Japanese
patients with IPF is significantly lower than that in
German patients with IPF [6]. These results suggest that
other genetic backgrounds may be present in the
Japanese population. More recently, research focus on
MUC4 promoter polymorphism indicated an association
with the development of DILD in Japanese patients, and
that the MUC4 promoter polymorphism may be associ-
ated with ethnic differences in the incidence of DILD.
These ethnic differences in promoter polymorphism
may account for the difference in incidence of DILD, in-
cluding that for loxoprofen.
In Japan, most pulmonologists diagnose patients with
DILD by the criteria developed by the Japanese Respira-
tory Society. These criteria suggest that the diagnosis of
DILD should be based on the history of treatment with
the suspected drug, absence of another disease (for
example, infection or pulmonary edema), improvement
after withdrawal of the suspected drug, and deterior-
ation after retreatment with the suspected drug [7]. In
addition, in Japan, a positive DLST is considered sig-
nificant evidence of DILD. We diagnosed this patient
with loxoprofen-induced pneumonia because of the de-
velopment of pneumonia after accidental retreatment
with loxoprofen, a treatment history of loxoprofen, and
exclusion of infection and pulmonary edema. Further-
more, our patient’s peripheral blood DLST for loxopro-
fen was strongly positive [8].
Her chest CT findings included peripheral, subpleural
peribronchovascular consolidation in both lungs in ac-
cordance with an organized pneumonia pattern [7, 9].
Although we were able to obtain BAL fluid for analysis,
we could not perform transbronchial lung biopsy because
of severe coughing during bronchoscopy. However, we
confirmed increased cell numbers and lymphocytes in her
BAL fluid. Subsequently, steroid pulse therapy was admin-
istered because progression of respiratory failure pre-
cluded further examination procedures.
Conclusions
Here we report the first case of loxoprofen-induced
pneumonia in the general population. Despite an un-
known incidence rate, clinicians should be aware of the
potential development of DILD after treatment with
loxoprofen.
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Table 1 Naranjo adverse drug reaction probability scale calculated for our case
Question Response Our case
1 Are there previous conclusive reports on this reaction? Yes +1
2 Did the adverse event appear after the suspected drug was given? Yes +2
3 Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? No 0
4 Did the adverse reaction appear when the drug was re-administered? Do not know 0
5 Are there alternative causes (other than the drug) that could have caused the reaction? Yes +2
6 Did the reaction reappear when a placebo was given? Do not know 0
7 Was the drug detected in any body fluid in toxic concentrations? Do not know 0
8 Was the reaction more severe when the dose was increased/increasing or less severe when the dose was decreased? No 0
9 Did the patient have a similar reaction to the same or similar drugs in any previous exposure? Yes +1
Total 6
Scoring: >9, definite ADR; 5–8, probable ADR; 1–4, possible ADR; 0, doubtful ADR. ADR adverse drug reaction
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